 Connection
James Burton to Male
This is a "connection" page, showing publications James Burton has written about Male.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.245 |
|
|
|
-
Burton JR, Helmke S, Lauriski S, Kittelson J, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Transl Res. 2021 07; 233:5-15.
Score: 0.032
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep; 61(3):508-14.
Score: 0.020
-
Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008 Sep; 49(3):329-38.
Score: 0.013
-
Burton JR, Liangpunsakul S, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol. 2007 Jul; 41(6):609-15.
Score: 0.012
-
Burton JR, Katon R. Anterograde colonoscopy: per oral diagnosis of colon cancer with an enteroscope in a man with a jejunoileal bypass. Gastrointest Endosc. 2003 Jun; 57(7):982-3.
Score: 0.009
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
Score: 0.008
-
Leff B, Burton L, Guido S, Greenough WB, Steinwachs D, Burton JR. Home hospital program: a pilot study. J Am Geriatr Soc. 1999 Jun; 47(6):697-702.
Score: 0.007
-
Rice J, Dodge JL, Bambha KM, Bajaj JS, Reddy KR, Gralla J, Ganapathy D, Mitrani R, Reuter B, Palecki J, Acharya C, Shaw J, Burton JR, Biggins SW. Neutrophil-to-Lymphocyte Ratio Associates Independently With?Mortality in Hospitalized Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018 11; 16(11):1786-1791.e1.
Score: 0.007
-
Dew MA, Butt Z, Liu Q, Simpson MA, Zee J, Ladner DP, Holtzman S, Smith AR, Pomfret EA, Merion RM, Gillespie BW, Sherker AH, Fisher RA, Olthoff KM, Burton JR, Terrault NA, Fox AN, DiMartini AF. Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort Study. Transplantation. 2018 01; 102(1):105-118.
Score: 0.006
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.006
-
O'Leary JG, Fontana RJ, Brown K, Burton JR, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb; 30(2):196-208.
Score: 0.006
-
Dew MA, DiMartini AF, Ladner DP, Simpson MA, Pomfret EA, Gillespie BW, Merion RM, Zee J, Smith AR, Holtzman S, Sherker AH, Weinrieb R, Fisher RA, Emond JC, Freise CE, Burton JR, Butt Z. Psychosocial Outcomes 3 to 10 Years After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study. Transplantation. 2016 Jun; 100(6):1257-69.
Score: 0.006
-
Brown RS, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
Score: 0.006
-
Olthoff KM, Smith AR, Abecassis M, Baker T, Emond JC, Berg CL, Beil CA, Burton JR, Fisher RA, Freise CE, Gillespie BW, Grant DR, Humar A, Kam I, Merion RM, Pomfret EA, Samstein B, Shaked A. Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg. 2015 Sep; 262(3):465-75; discussion 473-5.
Score: 0.005
-
Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
Score: 0.005
-
Rice J, Roberts H, Burton J, Pan J, States V, Rai SN, Galandiuk S. Assay reproducibility in clinical studies of plasma miRNA. PLoS One. 2015; 10(4):e0121948.
Score: 0.005
-
Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88.
Score: 0.005
-
Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, Py A, Pilcher GS, Fink CA, Burton JR, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol. 1994 Nov 15; 24(6):1439-44.
Score: 0.005
-
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
Score: 0.005
-
Moorehead KJ, Burton JR, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ. Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. J Antimicrob Chemother. 2015 Jan; 70(1):315-7.
Score: 0.005
-
Ladner DP, Dew MA, Forney S, Gillespie BW, Brown RS, Merion RM, Freise CE, Hayashi PH, Hong JC, Ashworth A, Berg CL, Burton JR, Shaked A, Butt Z. Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). J Hepatol. 2015 Feb; 62(2):346-53.
Score: 0.005
-
Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol. 2013 May; 58(5):969-76.
Score: 0.005
-
Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013 Jan 01; 62(1):67-73.
Score: 0.005
-
Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8.
Score: 0.004
-
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul; 143(1):88-98.e3; quiz e14.
Score: 0.004
-
Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, Kam I, Mandell S, Silliman CC, Rosen H, Moss M. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl. 2011 Feb; 17(2):149-58.
Score: 0.004
-
Berman K, Tandra S, Forssell K, Vuppalanchi R, Vuppalanch R, Burton JR, Nguyen J, Mullis D, Kwo P, Chalasani N. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):254-9.
Score: 0.004
-
Gloth FM, Burton JR. Autopsies and death certificates in the chronic care setting. J Am Geriatr Soc. 1990 Feb; 38(2):151-5.
Score: 0.004
-
Hothi DK, Rees L, Marek J, Burton J, McIntyre CW. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol. 2009 Apr; 4(4):790-7.
Score: 0.004
-
Burton JR, Pearce KL, Burgio KL, Engel BT, Whitehead WE. Behavioral training for urinary incontinence in elderly ambulatory patients. J Am Geriatr Soc. 1988 Aug; 36(8):693-8.
Score: 0.003
-
Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Tester IA, Wang CC, Culbertson N, Vandenbark AA, Rosen HR. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008 Jan 01; 197(1):46-57.
Score: 0.003
-
McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW, Neff G, Burton JR, Vargas H, Donovan J, Trotter J, Faust T. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
Score: 0.003
-
Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, Klarquist J, Belle SH. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007 Aug; 46(2):350-8.
Score: 0.003
-
Arjal RR, Burton JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):127-40.
Score: 0.003
-
Golden-Mason L, Burton JR, Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology. 2006 Nov; 44(5):1098-109.
Score: 0.003
-
Tresch DD, Simpson WM, Burton JR. Relationship of long-term and acute-care facilities. The problem of patient transfer and continuity of care. J Am Geriatr Soc. 1985 Dec; 33(12):819-26.
Score: 0.003
-
Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost. 2005 Mar; 3(3):439-47.
Score: 0.003
-
Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost. 2004 Feb; 2(2):234-41.
Score: 0.002
-
Molzahn AE, Burton JR, McCormick P, Modry DL, Soetaert P, Taylor P. Quality of life of candidates for and recipients of heart transplants. Can J Cardiol. 1997 Feb; 13(2):141-6.
Score: 0.002
-
Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol. 1997 Jan; 29(1):35-42.
Score: 0.002
-
Bergman H, Clarfield AM, Ouslander J, Kane R, Burton JR, Gold S. Same patients, different systems: clinical implications for the care of the elderly. J Am Geriatr Soc. 1992 Nov; 40(11):1178-82.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|